Featured Content

SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC

Evidence suggests that starting on systemic drug therapy immediately may be the best approach for some patients with metastatic RCC.

Is Real-World Evidence a Complement to Randomized Clinical Trials?

Use of real-world data has the potential to accelerate drug and device approvals in rare diseases and advance precision medicine initiatives.

Renal Cell Carcinoma: Treatment Paradigms in Octogenarians

Significantly fewer patients had radical nephrectomy in 2004 compared with 2015.

MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information

Three genes were confirmed to have prognostic value in RCC and were integrated into the MSKCC risk model toward the creation of a new, genomically ...

Gene-Delivery Method Generates Immune Checkpoint Antibodies In Vivo

In mice, DNA-encoded plasmids generated sufficient in vivo expression of immune checkpoint antibody CTLA-4; DMabs may one day rival traditional mAbs.

More Features>>>

Renal Cell Carcinoma Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs